Drug Development Pharma Companies Small Molecule 
DrugBaron
JULY 19, 2022
Despite the current hype around so called “advanced therapies”, which range from gene editing to cell therapies, and the inexorable advance of biologic therapeutics such as monoclonal antibodies, even in 2022 the majority of drugs in development and reaching patients are still small organic molecules.
DrugBaron
JANUARY 31, 2024
Billions of dollars have been invested in companies promising to “revolutionise pharma R&D” through the application of artificial intelligence – but it is now clear that global pharma companies, and not just tech bro’s, are buying into the claims. And there is no doubt that there is plenty of room for improvement.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Dark Matter Blog
JUNE 21, 2023
As a small biotech company with new technology at the frontier of the known drug discovery universe, it may feel like you’re charting a course alone in a dark, cold, and empty void with hailing frequencies open, but with no incoming transmissions. But you would be wrong.
Drug Target Review
MAY 23, 2023
Micro- and macroalgae from both marine and fresh water produce small molecules and secondary metabolites with aggregative, anti-inflammatory, antioxidant, antimicrobial, anti-viral and anti-tumoural bioactivities. Examples include phlorotannins from brown seaweeds and small molecules like terpenoids and peptides, found in microalgae.
PerkinElmer
FEBRUARY 18, 2021
Which high throughput screening (HTS) approach is the most productive in finding hits for drug development: target-based or phenotypic? By a 3:1 margin, PerkinElmer found top Pharma screens for a specific target. Small molecules are making a comeback. It is an ongoing debate.
Vial
FEBRUARY 19, 2024
Can you elaborate on how the platform allows your company to tailor therapy? We can link small molecule drugs to a payload that would enter in the cell and kill it. We have the capability of different types of targets, whether small molecules or antibodies. Ahmed Hamby: We also have a very cool modification.
Elrig
APRIL 29, 2024
There, I supported AI-enabled DD efforts in their small molecule portfolio. big pharma or startups/spin off? thanks Big pharma experienced is very well respected within biotech or small-startups. Where do you enjoy more to work? What pro/cons?
Expert insights. Personalized for you.
100 
Let's personalize your content